Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.
Leave a Response
You must be logged in to post a comment.
